|Association between premature mortality and hypopituitarism|
JW Tomlinson, N Holden, RK Hills, K Wheatley, RN Clayton, AS Bates, ...
The Lancet 357 (9254), 425-431, 2001
|11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response|
JW Tomlinson, EA Walker, IJ Bujalska, N Draper, GG Lavery, MS Cooper, ...
Endocrine reviews 25 (5), 831-866, 2004
|Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study|
MJ Armstrong, P Gaunt, GP Aithal, D Barton, D Hull, R Parker, ...
The Lancet 387 (10019), 679-690, 2016
|Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence|
S Thangaratinam, E Rogozińska, K Jolly, S Glinkowski, T Roseboom, ...
Bmj 344, 2012
|Pathogenesis of non-alcoholic fatty liver disease|
JK Dowman, JW Tomlinson, PN Newsome
QJM: An International Journal of Medicine 103 (2), 71-83, 2010
|Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis|
JK Dowman, JW Tomlinson, PN Newsome
Alimentary pharmacology & therapeutics 33 (5), 525-540, 2011
|Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency|
N Draper, EA Walker, IJ Bujalska, JW Tomlinson, SM Chalder, W Arlt, ...
Nature genetics 34 (4), 434-439, 2003
|Mortality in patients with pituitary disease|
M Sherlock, J Ayuk, JW Tomlinson, AA Toogood, A Aragon-Alonso, ...
Endocrine reviews 31 (3), 301-342, 2010
|Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines|
JW Tomlinson, J Moore, MS Cooper, I Bujalska, M Shahmanesh, C Burt, ...
Endocrinology 142 (5), 1982-1989, 2001
|Interventions to reduce or prevent obesity in pregnant women: a systematic review.|
S Thangaratinam, E Rogozińska, K Jolly, S Glinkowski, W Duda, ...
NIHR Health Technology Assessment programme: Executive Summaries, 2012
|Non-alcoholic fatty liver disease and diabetes|
JM Hazlehurst, C Woods, T Marjot, JF Cobbold, JW Tomlinson
Metabolism 65 (8), 1096-1108, 2016
|Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study|
AJ Sinclair, MA Burdon, PG Nightingale, AK Ball, P Good, TD Matthews, ...
Bmj 341, c2701, 2010
|Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione|
MW O'Reilly, AE Taylor, NJ Crabtree, BA Hughes, F Capper, RK Crowley, ...
The journal of clinical endocrinology & metabolism 99 (3), 1027-1036, 2014
|Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program|
MJ Armstrong, DD Houlihan, IA Rowe, WHO Clausen, B Elbrønd, ...
Alimentary pharmacology & therapeutics 37 (2), 234-242, 2013
|Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity|
JW Tomlinson, B Sinha, I Bujalska, M Hewison, PM Stewart
The Journal of Clinical Endocrinology & Metabolism 87 (12), 5630-5635, 2002
|Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis|
MJ Armstrong, D Hull, K Guo, D Barton, JM Hazlehurst, LL Gathercole, ...
Journal of hepatology 64 (2), 399-408, 2016
|Diagnosis and management of adrenal insufficiency|
I Bancos, S Hahner, J Tomlinson, W Arlt
The lancet Diabetes & endocrinology 3 (3), 216-226, 2015
|Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11β-hydroxysteroid dehydrogenase type 1|
IJ Bujalska, N Draper, Z Michailidou, JW Tomlinson, PC White, ...
Journal of Molecular Endocrinology 34 (3), 675-684, 2005
|11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus|
G Valsamakis, A Anwar, JW Tomlinson, CHL Shackleton, PG McTernan, ...
The Journal of Clinical Endocrinology & Metabolism 89 (9), 4755-4761, 2004
|11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess|
SA Morgan, EL McCabe, LL Gathercole, ZK Hassan-Smith, DP Larner, ...
Proceedings of the National Academy of Sciences 111 (24), E2482-E2491, 2014